Proteome and metaborome analyses for drug response in cancer patients with solid tumor receiving chemotherapy
Not Applicable
- Conditions
- Cancer
- Registration Number
- JPRN-UMIN000001356
- Lead Sponsor
- Saitama Medical University, International Medical Center, Department of Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with interstitial pneumonia or pulmonary fibrosis. 2)Patients with severe infection (with fever). 3)Patients with incontrollable diabetes. 4)Patients with severe heart failure. 5)Patients with severe complication such as cirrhosis. 6)Patients with mental or nerve disorder. 7)Pregnant patients or patients giving the breast. Men and wemen who want to make baby. 8)Patients with severe allergy or those who had severe allergy in the past. 9)Patients who are contraindication for cancer chamotherapy. 10)Patients hypersensitive to the anticancer drug(s). 11)Patients who are not appropriate to participate in the study safely.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Genetic polymorphisms in factors associated with pharmacokinetics and pharmacodynamics of anticancer drugs, proteome and metaborome, anticancer effects and adverse drug reactions.
- Secondary Outcome Measures
Name Time Method